CORRESPONDENCE years), and more patients were male (68.8% versus 67.9%), were
current or previous smokers (67.1% versus 60.1%), had an estimated glomerular filtration …

Background: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events
and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and …

Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue,
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …

In the last years, due to new regulatory guidelines requiring a stringent documentation of
cardiovascular (CV) safety of novel drugs for type 2 diabetes, cardiovascular outcomes …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce cardiovascular (CV) events
among patients with type 2 diabetes and high CV risk. Because consensus professional …

Glucagon-like peptide-1 is an incretin secreted in response to nutrient ingestion.
Derangements in the incretin system may contribute to the onset and progression of …

Glucagon‑like peptide‑1 receptor agonist liraglutide may have beneficial effects on
atherosclerosis development in impaired glucose tolerance (IGT). To the best of our …

Importance After the occurrence of nonfatal cardiovascular events, recurrent events are
highly likely. Most cardiovascular outcomes trials analyze first events only; extending …

Higher baseline LDL-C was associated with greater risk of MACEs. The crude proportion of
patients experiencing MACEs was 11.7% in the LDL-C< 50 mg/dL group, 13.9% in the LDL …

Background: Liraglutide is a novel, long-acting glucagon-like peptide-1 (GLP-1) analogue
used to treat type 2 diabetes mellitus. However, the cardiovascular safety and benefits of …